Q&A: Monoclonal antibody combinations appear equally effective against COVID-19

In the largest comparative randomized trial of monoclonal antibody treatments for COVID-19, two regimens — bamlanivimab/etesevimab and casirivimab/imdevimab — were safe and appeared to be equally effective, according to a press release.In the OPTIMISE-C19 trial, researchers from the University of Pittsburgh Medical Center compared the effectiveness of the combination regimens, both of

Read the full article here

Related Articles